SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Weinstock H,Berman S,Cates WJr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004; 36: 610.
  • 2
    Woodman CB,Collins S,Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001; 357: 18311836.
  • 3
    Moscicki AB,Shiboski S,Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998; 132: 277284.
  • 4
    Munoz N,Bosch FX,de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348: 518527.
  • 5
    Walboomers JM,Jacobs MV,Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 1219.
  • 6
    US Food and Drug Administration. Product approval information-licensing action, 2006. Available at: http://www.fda.gov/cber/products/hpvmer060806.htm. Accessed June 2008.
  • 7
    Harper DM,Franco EL,Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004; 364: 17571765.
  • 8
    Villa LL,Costa RL,Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6: 271278.
  • 9
    Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of 4 randomised clinical trials. Lancet. 2007; 369: 18611868.
  • 10
    Villa LL,Costa RL,Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006; 95: 14591466.
  • 11
    Paavonen J,Jenkins D,Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369: 21612170.
  • 12
    Markowitz LE,Dunne EF,Saraiya M,Lawson HW,Chesson H,Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-2): 124.
  • 13
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118: 30303044.
  • 14
    Bosch FX,de Sanjose S. Chapter 1: human papillomavirus and cervical cancer—burden and assessment of causality. Review. J Natl Cancer Inst Monogr. 2003; (31): 313.
  • 15
    Clifford GM,Smith JS,Aguado T,Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003; 89: 101105.
  • 16
    Castellsague X,Diaz M,de Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006; 98: 303315.
  • 17
    Srodon M,Stoler MH,Baber GB,Kurman RJ. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol. 2006; 30: 15131518.
  • 18
    Kreimer AR,Clifford GM,Boyle P,Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14: 467475.
  • 19
    Parkin DM,Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine. 2006; 24( suppl 3): S11S25.
  • 20
    Winer RL,Lee SK,Hughes JP,Adam DE,Kiviat NB,Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003; 157: 218226.
  • 21
    Burchell AN,Richardson H,Mahmud SM, et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol. 2006; 163: 534543.
  • 22
    Dunne EF,Unger ER,Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007; 297: 813819.
  • 23
    Manhart LE,Holmes KK,Koutsky LA, et al. Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis. 2006; 33: 502508.
  • 24
    Revzina NV,Diclemente RJ. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. Int J STD AIDS. 2005; 16: 528537.
  • 25
    Jacobson DL,Womack SD,Peralta L, et al. Concordance of human papillomavirus in the cervix and urine among inner city adolescents. Pediatr Infect Dis J. 2000; 19: 722728.
  • 26
    Burk RD,Ho GY,Beardsley L,Lempa M,Peters M,Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis. 1996; 174: 679689.
  • 27
    Kotloff KL,Wasserman SS,Russ K, et al. Detection of genital human papillomavirus and associated cytological abnormalities among college women. Sex Transm Dis. 1998; 25: 243250.
  • 28
    Datta SD,Koutsky LA,Ratelle S, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med. 2008; 148: 493500.
  • 29
    Dunne EF,Nielson CM,Stone KM,Markowitz LE,Giuliano AR. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis. 2006; 194: 10441057.
  • 30
    Nielson CM,Flores R,Harris RB, et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev. 2007; 16: 11071114.
  • 31
    Franceschi S,Herrero R,Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer. 2006; 119: 26772684.
  • 32
    Brown DR,Shew ML,Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005; 191: 182192.
  • 33
    Myers ER,McCrory DC,Nanda K,Bastian L,Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000; 151: 11581171.
  • 34
    Ho GY,Bierman R,Beardsley L,Chang CJ,Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998; 338: 423428.
  • 35
    Garcia-Pineres AJ,Hildesheim A,Herrero R, et al. Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res. 2006; 66: 1107011076.
  • 36
    Plummer M,Schiffman M,Castle PE,Maucort-Boulch D,Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007; 195: 15821589.
  • 37
    Garland SM,Hernandez-Avila M,Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356: 19281943.
  • 38
    The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356: 19151927.
  • 39
    Hildesheim A,Herrero R,Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007; 298: 743753.
  • 40
    Reisinger KS,Block SL,Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007; 26: 201209.
  • 41
    Pedersen C,Petaja T,Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007; 40: 564571.
  • 42
    Dias D,Van Doren J,Schlottmann S, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol. 2005; 12: 959969.
  • 43
    Harper DM,Franco EL,Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367: 12471255.
  • 44
    Block SL,Nolan T,Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006; 118: 21352145.
  • 45
    Villa LL,Ault KA,Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006; 24: 55715583.
  • 46
    Luna J,Saah A,Hood S,Bautista O,Barr E,for the FUTURE III Investigators. The safety, efficacy and immunogenicity of quadrivalent HPV (types 6/11/16/18) L1 virus-like particle (VLP) vaccine in women aged 24 to 45. Abstract PA1-04. International Papillomavirus Congress, Beijing, China, November 3-9, 2007.
  • 47
    Schwartz T,Descamps O, for the HPV Vaccine Study Group for Adult Women. Immune response in women up to 55 years of age vaccinated with cervarix, the HPV 16/18 L1 VLP AS04 vaccine candidate. EUROGIN October 4–6, 2007; SS23.
  • 48
    Brown D, for the FUTURE Study Group. HPV type 6/11/16/18 vaccine: first analysis of cross-protection against persistent infection, cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18. Abstract G-1720b: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 17-20, 2007.
  • 49
    American Academy of Pediatrics Committee on Infectious Diseases. Prevention of human papillomavirus infection: provisional recommendations for immunization of girls and women with quadrivalent human papillomavirus vaccine. Pediatrics. 2007; 120: 666668.
  • 50
    Saslow D,Castle PE,Cox JT. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007; 57: 728.
  • 51
    American Cancer Society. Recommendations for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Precancers. Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_6X_ACS_Recommendations_for_HPV_Vaccine_Use_to_Prevent_Cervical_Cancer_and_Pre-Cancers_8.asp. Accessed February 2, 2008.
  • 52
    American College of Obstetricians and Gynecologists. HPV vaccine-ACOG recommendations. Available at: http://www. acog.org/departments/dept_notice.cfm?recno=7&bulletin=3945. Accessed February 2, 2008.
  • 53
    Schiffman M. Integration of human papillomavirus vaccination, cytology, and testing. Cancer. 2007; 111: 145153.
  • 54
    Centers for Disease Control and Prevention (CDC). National vaccination coverage among adolescents aged 13-17 years—United States, 2006. MMWR Morb Mortal Wkly Rep. 2006; 56: 885888.
  • 55
    Iskander JK,Miller ER,Chen RT. The role of the Vaccine Adverse Event Reporting System (VAERS) in monitoring vaccine safety. Pediatr Ann. 2004; 33: 599606.
  • 56
    Destafano F. Vaccine Safety Datalink Research Group. The Vaccine Safety Datalink Project. Pharmacoepidemiol Drug Safety. 2001; 10: 403406.